The application of molecular biological tools to the study of cancer has significantly advanced the field of human cancer research. Such study has demonstrated the involvement of two classes of highly conserved cellular genes in the malignant transformation process: oncogenes and tumor suppressor genes. Despite these advances in the molecular biology of human cancers, our understanding of human oral cancer lags behind that of cancer of other body sites. This review attempts to assess the current status of the molecular biology of human oral cancer.
Introduction
O ral cancer is newly diagnosed in approximately 40,000 Americans and 350,000 others worldwide each year (Boring et al, 1992) . Oral cancer is the sixth most common cancer for both sexes in the general population, and the third most common cancer in developing nations. About half of the patients afflicted will die within five years of diagnosis, while surviving patients may be left with severe esthetic and/or functional compromise (Silverman, 1988; Vokes et al, 1993; Sidransky, 1995) . The International Classification of Diseases defines oral cancer as cancer of the oral cavity and pharynx, including cancer of the lip, tongue, salivary glands, gum, floor and other areas of the mouth, oropharynx, nasopharynx, hypopharynx, pharynx, and other buccal areas. Carcinomas account for 96% of all oral cancers, 91% of which are squamous cell carcinomas (Silverman and Gorsky, 1990) . Although there has been a reduction in total mortality over the past two decades, the five-year relative cancer survival rate for oral cancer is one of the lowest, far below the rate for many other cancers, including skin melanoma and cancer of the testis, breast, colon, rectum, and kidney. The National Cancer Institute Surveillance Epidemiology and End Result (SEER) Program for [1983] [1984] [1985] [1986] [1987] [1988] [1989] reported that only 33% of black patients and 54% of white patients survive the five-year period after detection of oral cancer.
The survival curves of oral cancer have plateaued over the past two decades and remain among the worst of all cancer sites. It is now clear that we need to advance our understanding of oral cancer etiology and development before further improvement can occur (Parkin et al, 1988; Schantz, 1993) . Tobacco and alcohol remain the most important risk factors for squamous cell carcinomas of the oral cavity (Vokes et al, 1993) . Viruses, most notably the human papillomavirus, have also long been linked to oral carcinogenesis (Brandama and Abramson, 1989; Howley, 1991; Park et al, 1991; Steele and Shillitoe, 1991; zur Hausen, 1991; Yeudall, 1992; Scully, 1993) . A genetic predisposition has also been suggested, due to the fact that the majority of the population exposed to these risk factors do not develop oral cancer, as well as the fact that sporadic cases of oral tumors occur in young adults and non-users of tobacco and alcohol (Lund and Howard, 1990; Shields and Harris, 1991) . Recently, many genetic events produced by chromosomal alterations caused by these risk factors have been proposed to underlie the histopathologic progression of oral squamous cell carcinoma (Field, 1992; Owens and Cohen, 1992) . It is therefore reasonable to hypothesize that early detection and/or treatment has played a role in the greater reduction of mortality over incidence. As with other forms of cancer, both the mortality and incidence data reflect higher rates among men than women and blacks than whites.
The molecular basis of human cancer is currently unfolding at a rapid pace with the use of multi-factorial approaches: molecular biology, virology, epidemiology, and clinical trials based on biological principles. This has previously been reviewed (Boyd and Reade, 1988; Field, 1992; Scully, 1993) , as has been the molecular virology of human oral cancer (Park et al, 1991; Steele and Shillitoe, 1991; Scully, 1993; Yeudall, 1992) . This review focuses on the current status of the molecular biology of human oral cancer.
Molecular Basis and Biology of Human Oral Cancer
Carcinogenesis is a complex, multi-step process in which genetic events within signal transduction pathways governing normal cellular physiology are quantitatively or qualitatively altered (Vogelstein and Kinzler, 1993) . The genetic basis of cancer is now well-established. Under normal conditions, these tightly controlled excitatory and inhibitory pathways regulate oral keratinocyte biology. Basic cellular functions under these controls include cell division, differentiation, senescence, and adhesion. These regulatory pathways are composed of extracellular ligands which bind to cell-surface receptors to generate intracellular signals sent through secondary messengers. These signals either directly alter cell function or stimulate the transcription of genes whose proteins effect change (Bishop, 1991) . Cancer is the result of an accumulation of changes in the excitatory and inhibitory cellular pathways, which may occur at any level of a given pathway. It has been estimated that from three to six somatic mutations are needed to transform a normal cell into its malignant counterpart (Vogelstein and Kinzler, 1993) . As the cell accumulates these alterations or mutations, it becomes functionally independent from the surrounding oral epithelium made up of normal oral keratinocytes (Sidransky, 1995) . The normal cellular functions tightly controlled by these regulatory pathways are subverted in tumor cells, thus enhancing the cell's ability to proliferate, stimulate neo-vascularization, and grow by invading locally or metastasizing to distant sites (Weiner and Cance, 1994) . The histologic progression of oral carcinogenesis is believed to reflect the accumulation of these changes (Field, 1992; Vokes et al, 1993) .
CYTOGENETICS OF HUMAN ORAL CANCER
In 1914, Boveri's study of tumor cell chromosomes led him to propose that alterations in chromosomes resulted in conversion of normal to malignant proliferation (Boveri, 1914) . For human oral cancer, the karyotypes of 63 short-term cultured tumors have been described Jin and Mertens, 1993; Partridge et al, 1994) . All karyotypes are complex, with great heterogeneity. Nonetheless, some genomic sites seemingly are non-randomly involved. There is the recurrent loss of chromosomes 9, 13, 18, and Y; deletions are frequently involved in the chromosome arms of 3p, 7q, 8p, 1 lq, and 17p, and in the short arm of all acrocentric chromosomes; and chromosome break points are frequently seen in the centromeric regions of chromosomes 1, 3, 8, 14, and 15 and in bands Ip22, Ilql3, and 19pl3 (Field, 1992; Jin and Mertens, 1993) . Since the cellular oncogenes bcl-l, int-2, and hst-\ have been mapped to 1 Iql3, while n-ras has been mapped to Ip22, it is proposed that activation of the oncogenes located in these bands may be preceded by cytogenetic mechanisms. Approximately two-thirds of all head and neck cancer cells contain a deleted region located in chromosome 9p21-22 (Ahsee et al, 1994; Nawroz et al, 1994 ), which appears in dysplastic and carcinoma in situ (CIS) lesions, thereby suggesting that a gene in this region is knocked out early in oral carcinogenesis . A tumor suppressor gene (TSG) initially isolated from melanoma cells, pl6 (MTS1 or CDKN2), is also found in this region and may prove to be a cell-cycle inhibitor important in oral cancer development (Serrano and Hannon, 1993; Kambetal, 1994; Van der Riet et al, 1994) . Chromosomal regions in 3p and 13q also contain regions frequently deleted and may yield new tumor suppressor genes of oral carcinogenesis (Sidransky, 1995) .
Genetic damage in oral cancer cells can be divided into two categories. Dominant changes, most frequently occurring in proto-oncogenes but also in certain TSGs, result in gain of function. Recessive changes, mutations most frequently noted in growth-inhibitory pathway genes or commonly in tumor suppressor genes, cause loss of function (Bishop, 1991) .
ONCOGENES IMPLICATED IN HUMAN ORAL CANCER
Oncogenes, gain-of-function mutations of highly regulated normal cellular counterparts (proto-oncogenes), are likely involved in the initiation and progression of oral neoplasia (Field, 1992) . Cellular oncogenes were initially discovered by the ability of tumor cell DNA to induce transformation in gene transfer assays (Shih et al, 1981) . These experiments have led to the identification of more than 60 cellular oncogenes (Cooper, 1995) . Mechanisms of activation of these cellular oncogenes include point mutations and DNA re-arrangements. Several of these cellular oncogenes are homologs of retroviral oncogenes (e.g., the ras genes); others are new oncogenes.
Several oncogenes have been implicated in oral carcinogenesis (Field, 1992) . Aberrant expression of the proto-oncogene epidermal growth factor receptor (EGFR)/c-erb 1, members of the ras family, as well as cmyc, int-2, hst-\, PRAD-1, and bcl-\, is believed to contribute to oral cancer development (Berenson et al, 1989; Wong et al, 1989; Merritt et al, 1990; Riviere et al, 1990; Somers et al, 1990; Sidransky, 1995) . Overexpression and amplification of cellular oncogene c~erb Bl have been reported in a DMBA-induced hamster cheek pouch malignant oral cancer model (Wong and Biswas, 1987) . We have shown transforming growth factor-alpha (TGFa) to be aberrantly expressed in human oral cancer and in hamster oral tumor (Wong et al, 1988; Todd et al, 1989 Todd et al, , 1991 , and it has been postulated that TGF-a promotes neovascularization and mitogenesis .
Growth factors
Growth factors can stimulate oral keratinocyte proliferation (Aaronson, 1991; Issing et al, 1993) . During oral carcinogenesis, growth factors are de-regulated through increased production and autocrine stimulation (Sporn and Todaro, 1980; Wong et al, 1990; Todd et al, 1991) . TGF-a is overexpressed early in oral carcinogenesis by hyperplastic epithelium and later by the inflammatory infiltrate, particularly the eosinophils, surrounding the invading oral epithelium Todd et al, 1991) . The increase in eosinophils in oral cancer-up to 17% of the total inflammatory infiltrate-was noted as early as 1975 by Healy (Healy, 1975) , and this is a consistent feature in all cases of oral cancer examined. TGF-a is a 50-amino-acid polypeptide that promotes cell proliferation in oral tissues as well as in other cell types in the body. TGF-a stimulates a target cell by binding to the epidermal growth factor receptor (EGFR) in an autocrine or paracrine fashion (Derynck, 1992) . Overexpression of this growth factor in transgenic mice led to epithelial hyperplasia and malignant transformation of mammary epithelium (Ihappan et al, 1990; Matsui et al, 1990; Sandgren et al, 1990) . In addition, TGF-a likely serves a tumor-promoting role in epithelial carcinogenesis (Sandgren et al, 1993; Coffey et al, 1994) . In head and neck cancer patients who later develop second primary cancers, "normal" oral mucosa oversecretes TGF-a, suggesting a "premalignant" state of rapid proliferation and genetic instability of the epithelium (Grandis and Tweardy, 1993) . Concomitant expression of TGF-a and EGFR may indicate more aggressive tumors than those overexpressing EGFR alone (Issing et al, 1993) .
Cell-surface receptors
Ligand receptor binding activates a cascade of intracellular biochemical steps (Aaronson, 1991) . Regulation of protein phosphorylation is an important event in cellular function and gene expression. Mutations of genes encoding cell-surface receptors can result in an increased number of receptors or production of a constituent ligand-independent mitogenic signal (Bishop, 1991; Cantley etal, 1991; Hunter, 1991) .
EGFR, the biological receptor of EGF and TGF-a, is a 170,000-dalton phosphoglycoprotein frequently found to be overexpressed in human oral cancers (Partridge et al, 1988; Shin et al, 1990; Todd et al, 1991; Rikimaru et al, 1992; Saranath et al, 1992; Grandis and Tweardy, 1993) . Malignant oral keratinocytes possess from 5 to 50 times more EGFR than their normal counterparts (Christensen et al, 1993) . Currently, three mechanisms have been postulated to activate the EGFR gene in carcinogenesis: (1) deletions or mutations in the N-terminal ligand-binding domain such as those occurring in the viral oncogene verbB (Downward et al, 1984; Ullrich et al, 1984) ; (2) overexpression of the EGFR gene concurrent with the continuous presence of EGF and/or TGF-a (Di Fiore et al, 1987; Di Marco et al, 1989) ; and (3) deletion in the C-terminus of the receptor, which prevents down-regulation of the receptor after ligand binding (Wells et al, 1988; Batra et al, 1994) . It is important to note that most of the current data on EGFR and cancer are based on molecular studies of human gliomas (Batra et al, 1994) . Similar studies in human oral cancer have not been performed. It is therefore of great importance to conduct studies to determine the spectrum of mutations in the human EGFR gene in order to gain a better insight into the mechanisms responsible for the overexpression of this frequently activated biomarker in human oral cancer. The molecular mechanisms responsible for the overexpression are not fully understood. EGFR gene amplification is detected in about 30% of cases (Scully, 1993) , which suggests that other mechanisms are responsible for the majority of EGFR overexpression. Whether the mutation in the EGFR gene results in overexpression of normal receptors, formation of receptors that can signal without stimulation, or a combination of the two in oral cancer is presently not understood. Oral tumors overexpressing EGFR exhibit a higher proportion of complete responses to chemotherapy than tumors with low-level EGFR expression. Overexpression of EGFR presumably due to higher intrinsic proliferative activity could result in higher sensitivity to drug therapy cytotoxic to cells undergoing mitogenesis (Santini et al, 1991) .
Intracellular messengers
Intracellular messengers can also be intrinsically activated, thereby delivering a continuous rather than a ligandregulated signal (Cantley etal, 1991; Hunter, 1991) . Of all the members of the intracellular signaling pathway, only members of the ras gene family (H-ras, K-ras, N-ras) have been examined in human oral cancer. The ras oncogenes were first identified in the murine Harvey and Kirsten sarcoma retroviruses. They all encode for the related protein p21 that has been localized to the cytoplasmic side of the cellular membrane. Of importance is the realization that the ras proteins bind guanine nucleotides (GDP and GTP) with high affinity and specificity. The ras proteins were eventually shown to be analogous to the G proteins in coupling receptors to intracellular secondary messengers (Shih et al, 1980) . The ras proteins transmit mitogenic signals by binding GTP. Hydrolysis of GTP to GDP ends the signal. Members of the ras gene family are mutated in approximately 30% of all human tumors (Bos, 1989) . However, the role of mutated ras genes in human oral carcinogenesis is presently not clear. A report from India demonstrated that 35% of oral squamous cell carcinomas contained H-ras mutations (Saranath et al, 1991) . However, studies from the Western world have shown that H-ras mutations are found in fewer than 5% of head and neck cancers (Rumsby et al, 1990; Sheng et al, 1990; Chang et al, 1991; Hirano et al, 1991) . In oral cancer, Kirsten ras (K-ras) has been shown to be activated by a point mutation (Spandidos et al, 1985) ; thus, it remains activated, but unable to hydrolyze GTP due to an amino acid change resulting from this mutation (Barbacid, 1987) . Because K-ras cannot convert GTP to GDP, it continues to stimulate the cell to proliferate. In a hamster oral cancer model, the c-Ha~ras and the c-erbB oncogenes were shown to be sequentially expressed during oral carcinogenesis (Husain et al, 1989) . Mutation in codon 61 of the Ha-ras gene was identified as an early event in this rodent oral cancer model (Kwong et al, 1992) .
Transcription factors
Transcription factors, or proteins that regulate the expression of other genes, are also altered in oral cancer. Modulation of gene expression is an important outcome in the alteration of the intracellular pathways (Bishop, 1991) . The transcription factor c-myc, which helps regulate cell proliferation and differentiation, is frequently overexpressed in oral cancers (Spandidos et al, 1985; Field, 1992) . Overexpression due to gene amplification of c-myc is most frequently associated with poorly differentiated tumors and with poor prognosis (Schantz, 1995) . The genes whose expression is stimulated by c-myc and their significance to oral carcinogenesis are poorly understood. Another transcription factor, the cell-cycle promoter PRAD1 (also CCND1 or cyclin Dl), is a cellcycle promoter that is also amplified in head and neck cancers (Callender et al, 1994) . While cyclin Dl is an important promoter of cell proliferation, its importance to oral cancer development is also under investigation.
While no particular order of oncogene activation has been demonstrated in oral or in other cancers, the accumulation of activated oncogenes appears to be of primary importance (Sidransky, 1995) . The importance of the presently identified oncoproteins to oral carcinogenesis is currently under investigation. Other oncogenes linked to oral cancer development are fet-1, int-2, bd-\, sea, men-1, and emsA (Field, 1992; Vokes et al, 1993) . However, oncogenes alone are not sufficient to cause oral cancer but appear to be initiators of the process. The critical event in the transformation of a premalignant cell to a malignant cell is the inactivation of cellular negative regulators, tumor suppressor genes.
TUMOR SUPPRESSOR GENES (TSGS)
Tumor suppressor genes or anti-oncogenes have been documented to confer potent negative regulatory controls which are lost due to chromosomal alterations during tumor formation. Functional loss of multiple tumor suppressor genes is believed to be the major event leading to the development of malignancy (Lee, 1993; Yokota and Sugimura, 1993) . Unlike oncogenes, which can effect a cellular change through mutation of only one of the two gene copies, tumor suppressor genes are most often inactivated by point mutations, deletions, and rearrangements in both gene copies in a "two-hit" fashion. Therefore, the critical events for the malignant transformation of oral keratinocytes, i.e., the loss of function of tumor suppressor genes, are difficult to achieve. This may account, in part, for the length of time required for the formation of adult solid tumors, such as oral cancers.
Many tumor suppressor genes were initially identified in pediatric tumors that formed early in life because one mutated tumor suppressor gene had been inherited. However, identification of these genes lagged a decade behind the isolation of the first oncogenes, because, in cancer cells, tumor suppressor genes are a negative phenotype-an event no longer present within the cell. Through mathematical models analyzing genetic pedigrees of pediatric tumor patients, Knudson predicted that the inactivation of both copies of tumor suppressor genes occurs in a two-hit fashion (Knudson, 1977) . Experimental evidence followed with the observation that normal:tumor hybrids demonstrated normal phenotypes, which suggested that normal cells contained suppressors of the tumor phenotype (Stanbridge, 1981) . These same experiments have been performed with normal and malignant oral keratinocytes (Moroco et al, 1990) . Only after extensive "chromosomal walking" analysis of pediatric tumors with large chromosomal alterations were the first tumor suppressor genes isolated (Bookstein and Lee, 1991) . Therefore, while the identification of these "cancer genes" is one of the primary focuses of tumor biologists today, far less is known about tumor suppressor genes. To date, only three genes-p53, doc-I, and thrombospondin 1-have exhibited tumor suppressor activity in malignant oral keratinocytes (Rastinejad et al, 1989; Good et al, 1990; Liu et al, 1994; Toddetal, 1995) .
P53
The tumor suppressor gene p53 is known to be mutated in approximately 70% of adult solid tumors (Hollstein et al, 1991) . Identification of members of its suppressor pathway, which themselves may be altered, may prove the importance of p53 to a higher percentage of cancers (Schantz, 1995) . In normal cell biology, p53 acts as a regulator of DNA synthesis. When genomic DNA is dam-aged, p53 is produced to block cell division at the Gl-S boundary and stimulate DNA repair (Hartwell and Kastan, 1994) . p53 also activate pathways leading to apoptosis. Mutation of p53 allows tumors to pass through the Gl-S boundary and propagate the genetic alterations that lead to other activated oncogenes or inactivated tumor suppressor genes. The p53 gene appears to be mutated at the transition of superficial to invasive carcinoma (Sidransky et al, 1993) . Alteration of the p53 gene occurs as point mutations and deletions. Point mutations result in a structurally altered protein that sequesters the wild-type protein, thereby inactivating it in a "dominant-negative" fashion. Deletions lead to a reduction and loss of p53 expression and protein function. Not only has p53 been demonstrated to be functionally inactivated in oral tumors, but also restoration of p53 function in oral cancer cell lines and in oral tumors induced in animal models results in the reversion of the malignant phenotype, thereby turning back oral carcinogenesis (Schantz, 1995) .
It should be noted that p53 has been shown to interact with the oncogenic protein E6 of the human papilloma virus (HPV), which results in the rapid degradation of the p53 protein by the ubiquitin-mediated proteolysis system (Scheffner et al, 1990; Werness et al, 1990) . Similar interaction has been shown for the HPV E7 protein with pRB (Dyson et al, 1989) , which interferes with the regulation of the activity of the E2F transcription factor family, a phenomenon that has profound consequences for the proliferative pattern of the affected cells. Given the overwhelming body of both epidemiologic and laboratory evidence of an association between HPV infection and cervical cancer, HPV can now be considered causal in the etiology of cervical cancer. Similar mechanisms may be involved in oral carcinogenesis.
Smoking and tobacco use have been associated with mutation of the p53 gene in squamous cell carcinoma (SCC) of the head and neck. By immunohistochemistry, p53 expression has been shown in oral tumors from patients who were heavy smokers and drinkers (Langdon and Partridge, 1992) . These authors suggested that alterations in the p53 gene may be one of the sites of genetic damage in oral cancer. Polymerase chain-reaction (PCR) has been used recently to show an association between a history of tobacco and alcohol use and a high frequency of p53 mutations in patients with SCC of the head and neck (Brennan et al, 1995) : Thirty-eight out of 81 smokers had p53 mutations, in contrast to three of 21 non-smokers, the most common mutations being GC to TA and GC to AT. These transversions, which are also the most common in lung cancer tumors, have been attributed to the mutagenic components of cigarette smoke, such as the polycyclic aromatic hydrocarbon benzo(a)pyrene (Greenblatt et al, 1994 ). Yet another recent study found no association between elevated p53 expression and tobacco smoking or alcohol intake: Five of nine non-smoking men displayed alterations in p53 compared with nine of 14 men who were heavy smokers (Franceschi etal, 1995) . Clearly, in light of these findings, further research is needed to explore the correlation between p53 mutations and environmental carcinogens.
dool
Using the hamster oral cancer model, we have identified and cloned a novel oral tumor suppressor gene named "deleted in oral cancer-1" (doc-\). Mutation of this gene in oral keratinocytes leads to a reduction of expression and protein production (Todd et al, 1995) . Re-expression of doc-\ in malignant oral keratinocytes results in the reversion of many malignant phenotypes to normal, thus causing the doc-1-transfected oral cancer cell to look and act like its normal counterpart. The precise function of doc-\ in normal oral keratinocyte biology is presently unclear. However, through a Genbank sequence search, we have matched the hamster doc~\ gene to a gene induced by tumor necrosis factor-alpha (TNF-a) in normal murine fibroblasts (Gordon et al, 1992) , thereby establishing a linkage of a tumoricidal cytokine to a tumor suppressor gene and suggesting doc-\ to be a downstream mediator of TNF-a's biological action, such as apoptosis. Experiments are currently in progress to test this hypothesis.
Thrombospondin 1
A series of elegant studies from the laboratories of Noel Bouck and Peter Polverini has linked suppression of tumor-induced angiogenesis with thrombospondin 1 (TSPl) (RastinejadeUl., 1989; Good etal, 1990; Polverini, 1995) . Using the hamster cheek pouch oral cancer model, Moroco et al have shown that the control of angiogenesis was lost during oral carcinogenesis (Moroco et al, 1990) . This loss of the regulation of the angiogenic phenotype in the malignant keratinocytes was correlated with a reduction of TSP1 in the conditioned media (Polverini, 1995) .
Oral growth suppressors and the signal transduction pathway
As oncogenes subvert pathways leading to growth promotion, inactivation of tumor suppressor genes cripples growth-inhibitory pathways. These events can occur at any level of the growth-inhibitory signal transduction pathway. Several extracellular ligands are oral keratinocyte growth inhibitors. TNF-a and transforming growth factor-beta (TGF-P) may provide important growth-inhibitory signals in oral epithelial cell biology. TNF-a, alone and with interferon-7, has been demonstrated to inhibit malignant oral keratinocyte proliferation (Aaronson, 1991; Howe et al, 1991; Sacchi et al, 1991) . TGF-p is an inhibitor of keratinocyte proliferation 7(4): 319-328 (1996) whose activity is due, in part, to a known tumor suppressor gene, the retinoblastoma susceptibility gene (Rb) (Moses et al, 1990; Bookstein and Lee, 1991; Irish, 1992) . While TNF-a and TGF-p have been linked to tumor suppressor gene pathways in other tumors, their significance in oral carcinogenesis is only speculative.
Cell-surface molecules may also be important in inhibiting oral keratinocyte proliferation. E-cadherin, a cell-cell adhesion molecule associated with both invasion and metastasis, is down-regulated in oral cancers (Behrens et al, 1989) . Deleted in colon cancer (DCC) is a N-CAM-like molecule believed to be an important cellcell contact inhibitor that is mutated during oral cancer development (Kim et al, 1993) .
Growth suppressor intracellular messengers may include the adenomatous polyposis coli (APC) gene, a Glike protein frequently mutated in certain familial colorectal cancers (Groden etal, 1991) . Recent evidence suggests that the APC gene may be altered in premalignant oral lesions (Largey et al, 1993) .
The transcription factor Rb, a known tumor suppressor gene, has been shown to have reduced expression in a small percentage of oral tumors but has yet to exhibit any tumor suppressor activity in oral cancer cells (Kim et al, 1993) .
Retinoic acid receptor-beta (RAR-a) is down-regulated in head and neck cancers (Brenner et al, 1994) . Retinoids are currently under investigation for prevention and reversion of oral premalignant lesions (DeLuca, 1991; Lotan etal., 1995) .
Conclusions
It is clear from this and other recent reviews that research on oral cancer lags behind that on cancer from other sites. However, efforts are intensifying through research aiming to expand the knowledge base of human oral cancer. There is a great need for improved diagnosis and management of pre-cancerous epithelium. The spectrum of research activities aimed at reducing the incidence and increasing the early diagnosis and treatment of oral cancer ranges from basic science laboratory research to human clinical trials. Today, no single laboratory can hope to master all modes of investigation, which include modern molecular biology, somatic cell genetic technologies, sophisticated and novel cell-culture techniques, molecular epidemiology analysis, and the treatment of oral cancer patients with biologically based therapy, including gene therapy (Shillitoe et al, 1994) . A successful oral cancer research program must therefore integrate these diverse but intimately related scientific disciplines into a planned and focused program that binds together their strengths and guides them toward mutually accepted goals. It is now essential to create a localized, collaborative network of scientists from different specialties, each with new or established interests in oral cancer, for scientific vigor and rapid progress in investigative oral cancer research.
